Professor of Hepatology at University College London
Yaqrit
Yaqrit Limited specializes in developing therapeutic interventions for liver disease, leveraging two decades of research from UCL to create targeted treatments. The company addresses the critical need for effective solutions in managing liver conditions, improving patient outcomes through evidence-based methodologies.
- Biotechnology
Updated 23 months ago
Funding
Raised to date
$2.8MRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Funding rounds are not available yet.
Founders
Product
Problem
Liver disease represents a significant global health challenge, with limited effective therapeutic interventions available to address the underlying causes and progression of these conditions. The absence of targeted treatments results in poor patient outcomes and a substantial burden on healthcare systems.
Solution
Yaqrit Limited is developing therapeutic interventions for liver disease, utilizing research to create targeted treatments. The company aims to address the unmet need for effective solutions in managing liver conditions and improving patient outcomes. By focusing on evidence-based methodologies, Yaqrit seeks to provide innovative approaches to combat liver disease.
Target Audience
The primary target audience includes patients suffering from liver diseases and healthcare professionals involved in their care.
Features
- Development of targeted therapeutic interventions for liver disease.
- Focus on evidence-based methodologies.
- Aims to improve patient outcomes in liver disease management.